|
Market Cap (16-May) $8,414,961,152 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (5-May) 16,072,273 (4.76%) (53rd) |
|
52w High $31.97 |
52w Low $14.42 |
P/E 57.80 |
EPS 0.15 |
TLX released this announcement to the ASX on 10 May 2021, 8:21. The announcement is marked as price sensitive, and is 2 page(s) in length and 217.94kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 1.181% short sold according to ASIC data. It was ranked the 161st most shorted stock on the ASX. It is now ranked as the 53rd most shorted stock on the ASX with 4.757% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| Phase III Prostate Cancer Therapy Clinical Trial Commences | 10 May 2021, 8:21 |
| Executive Leadership Appointments and Establishment of APAC | 3 May 2021, 8:08 |
| Telix Appoints Mr Richard Valeix as EMEA President | 3 May 2021, 8:08 |
| Manufacturing Agreement with Global Medical Solutions | 27 April 2021, 8:21 |
You must be logged in to post a reply.
Telix Pharmaceuticals 